《港股》恆指半日升47點 阿里美團造好 內房股下滑
內地第二季經濟增長5.2%勝預期,上月零售銷售及固定投資增長遜預期,工業產出則勝預期。港股早市曾升逾300點後升幅收窄。恆指高開78點,早段曾升352點高見24,555點,其後曾倒跌61點見24,141點,半日升47點或0.2%,報24,250點;國指升8點或0.1%,報8,741點;恆生科技指數升21點或0.4%,報5,305點。大市半日成交總額1,439.96億元。
科技股方面,據報阿里加入外賣大戰,計劃打造「超級星期六」,阿里(09988.HK)及美團(03690.HK)升1.7%及1.6%,京東(09618.HK)跌0.6%。英偉達行政總裁黃仁勳稱H20晶片對華銷售將獲美方允許,中芯(00981.HK)跌2.4%。嗶哩嗶哩(09626.HK)升4.8%。
騰訊(00700.HK)及百度(09888.HK)升0.6%,網易(09999.HK)及快手(01024.HK)升1.6%及1.2%。萬國數據(09698.HK)續升10.2%,金山雲(03896.HK)續升7.8%。騰訊音樂(01698.HK)升5%,手機部件股瑞聲(02018.HK)及高偉電子(01415.HK)升4.7%及4%。越疆(02432.HK)折讓9.5%配股淨籌10.2億元,股價跌3.8%。
車股蔚來(09866.HK)升2.3%,比亞迪(01211.HK)平收報120.4元。小米(01810.HK)跌0.6%。鋰業股贛鋒(01772.HK)跌6%,公司料半年虧損3億至5.5億人民幣。消費內需股方面,南航(01055.HK)預告半年虧損最多17.56億人民幣,股價跌4%。
醫藥股諾誠健華(09969.HK)、百濟神州(06160.HK)及石藥(01093.HK)升3.9%至5.4%。康哲藥業(00867.HK)及中生製藥(01177.HK)升3.2%及3%,恆瑞(01276.HK)及康龍化成(03759.HK)跌2.9%及3.2%。亞盛醫藥(06855.HK)折讓8.2%先舊後新配股淨籌逾14.9億元,股價跌3.9%。
內房股回吐,富力(02777.HK)、遠洋(03377.HK)及合景泰富(01813.HK)跌6.3%至7%,雅居樂(03383.HK)跌8.8%,金茂(00817.HK)及融創(01918.HK)跌逾5%。萬科(02202.HK)預計半年虧損100億至120億人民幣,半日股價跌3.9%。水泥股海螺水泥(00914.HK)及金隅(02009.HK)跌3.9%及7%,金隔預計半年虧損13億至16億元人民幣。
內險股國壽(02628.HK)、人保(01339.HK)、太保(02601.HK)及眾安在線(06060.HK)跌2.4%至3.2%,券商股國泰海通(02611.HK)、廣發証券(01776.HK)及中金(03908.HK)跌2.6%至3.5%。據報招行(03968.HK)全資附屬招銀國際獲批虛擬資產牌照,招行跌0.9%,同系招商證券(06099.HK)炒高5.4%。國泰君安國際(01788.HK)及耀才(01428.HK)跌3.6%及6.2%。其他金融股方面,匯控(00005.HK)及友邦(01299.HK)升0.9%及0.2%,渣打(02888.HK)升2.1%,港交所(00388.HK)平收報423.6元。
美國對多晶矽進口展開調查,信義玻璃(00868.HK)、信義光能(00968.HK)及福萊特玻璃(06865.HK)跌4.4%至5%,協鑫科技(03800.HK)跌7%。其他股份方面,健康之路(02587.HK)升10.5%,香港中旅(00308.HK)升2.3%。據報新世界(00017.HK)未能如期獲得20億美元貸款,磋商仍在進行,新世界跌1.6%,中國白銀(00815.HK)折讓19.64%發新股籌淨額2.06億元,股價跌8.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.